Ignite Creation Date:
2024-05-06 @ 6:21 PM
Last Modification Date:
2024-10-26 @ 2:46 PM
Study NCT ID:
NCT05638594
Status:
RECRUITING
Last Update Posted:
2023-03-20
First Post:
2022-11-24
Brief Title:
Pyrotinib Combined With Trastuzumab Dalpiciclib Letrozole Versus TCbHP Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin as Neoadjuvant Treatment in HR HER2 Breast Cancer
Sponsor:
Shengjing Hospital
Organization:
Shengjing Hospital
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-12-20
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-10
Completion Date Type:
ESTIMATED
First Submit Date:
2022-11-24
First Submit QC Date:
December 2 2022
Study First Post Date:
2022-12-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-03-16
Last Update Post Date:
2023-03-20
Last Update Post Date Type:
ACTUAL